Mazdutide's GLORY-2 Trial Just Dropped -- Here's the New Signal in China's Weight Loss Race

There's a new obesity drug trial out of China that most people outside the research world haven't heard of yet. It's called GLORY-2, and it just tested a drug called mazdutide -- a peptide built differently than Ozempic or Zepbound -- in Chinese adults with obesity.

Here's why that's worth your attention before it hits the mainstream news cycle: mazdutide doesn't just mimic GLP-1 like semaglutide does. It also activates glucagon receptors, which is a mechanism most of the GLP-1 drugs Americans know about don't touch. Not medical advice: I'm not a doctor. Everything below is based on published research and reporting, not personal recommendations. Talk to your physician before making any changes to your health regimen.

The Bottom Line

• What's new: GLORY-2 is a randomized clinical trial testing 9mg mazdutide, a dual GLP-1/glucagon receptor peptide, for weight loss in Chinese adults with obesity.
• Why it matters: Mazdutide's dual mechanism is designed to burn more energy, not just suppress appetite -- a different approach than single-target GLP-1 drugs like semaglutide.
• What the data suggests: Participants on the 9mg dose lost a meaningful amount of body weight, in a range that puts mazdutide in the same conversation as tirzepatide, not far behind it.
• What it means for you: Mazdutide isn't approved or available in the US yet, but this trial is a signal that the next wave of weight-loss peptides is moving past single-hormone drugs toward multi-receptor combos.
• Actionable takeaway: If you're deciding between GLP-1 options today, this is a good moment to understand why dual and triple agonists exist -- it'll help you make sense of what's coming next, covered in our dual vs. triple agonist breakdown.

What Is Mazdutide, and Why Is Everyone Suddenly Talking About It?

Mazdutide is a peptide developed in China that acts on two receptors at once: GLP-1 and glucagon. Semaglutide (Ozempic, Wegovy) only hits the GLP-1 receptor. Tirzepatide (Mounjaro, Zepbound) hits GLP-1 and a second receptor called GIP.

Mazdutide takes a different combo. Glucagon receptor activation is associated with increased energy expenditure -- basically, your body burning more calories at rest -- on top of the appetite reduction GLP-1 already provides.

That's the theory, anyway. GLORY-2 is one of the trials designed to test whether that theory holds up in real people, not just in a lab.

What GLORY-2 Actually Tested

GLORY-2 was a randomized clinical trial looking at 9mg mazdutide for weight reduction specifically in Chinese adults with obesity (Source: PubMed). Participants were split into groups, with one group receiving the 9mg dose and others receiving lower doses or placebo, then tracked over time to see how much weight they lost and how their bodies responded.

This matters because most of the big GLP-1 trials you've heard about -- STEP, SURMOUNT -- were run mostly in Western populations. Body composition, baseline metabolic rates, and even average BMI thresholds for "obesity" differ in Chinese populations, so testing the drug specifically in this group fills a real gap in the research.

Earlier mazdutide trials (part of the same development program) reported weight loss in the range of 14% to 15% of body weight at the 9mg dose over roughly a year, which is in the same ballpark as tirzepatide's published results and ahead of what most semaglutide trials show. GLORY-2 builds on that earlier data with a more focused, controlled comparison at the highest studied dose.

Why the Dual-Receptor Approach Is the Real Story Here

This is the part that deserves the "new signal" label. Appetite suppression alone -- the main way GLP-1 drugs work -- gets people to eat less. That's effective, but it's only half the equation.

Glucagon receptor activation is thought to nudge the body toward burning stored fat for energy, independent of how much someone eats. Researchers have been chasing this combination for years because it could mean:

• Comparable or better weight loss than single-target drugs
• Potentially less muscle loss relative to fat loss (though this needs more direct study)
• A mechanism that doesn't rely purely on eating less, which matters for people who plateau on appetite suppression alone

None of this is confirmed as superior to existing drugs yet -- it's a promising signal, not a settled answer. A recent network meta-analysis comparing obesity drugs found that head-to-head differences between mechanisms still need more direct trial data before conclusions can be drawn with confidence (Source: BMJ, 2026).

How Does This Compare to Semaglutide and Tirzepatide?

If you're already familiar with the semaglutide vs. tirzepatide conversation, mazdutide slots in as a third option built on a different combination of receptors entirely. Here's the simple version:

Drug	Receptors targeted	Mechanism focus
Semaglutide	GLP-1 only	Appetite suppression, slower digestion
Tirzepatide	GLP-1 + GIP	Appetite suppression + insulin sensitivity
Mazdutide	GLP-1 + glucagon	Appetite suppression + energy expenditure

This isn't the first time a glucagon-receptor combo has been tested -- retatrutide, for example, is a triple agonist that also hits glucagon receptors alongside GLP-1 and GIP. If you want to see how that triple-target approach performs, our retatrutide vs. tirzepatide comparison covers the differences in more depth.

What About Side Effects?

Every GLP-1-class drug comes with a similar side effect list: nausea, constipation, and stomach discomfort, especially when starting or increasing the dose. Mazdutide's early trials reported a similar pattern, with gastrointestinal side effects being the most common reason people stopped taking it.

Glucagon receptor activation adds a theoretical concern worth watching: glucagon can raise blood sugar in some contexts, which is the opposite of what you'd want in a metabolic drug. Researchers designing these combo drugs balance the ratio of GLP-1 to glucagon activity specifically to avoid this, but it's something long-term safety data will need to confirm.

This is also why broader safety monitoring across the GLP-1 drug class matters. A recent multicentre cohort study looking at major safety outcomes for GLP-1 receptor agonists used for weight loss found the drugs were generally well-tolerated, though it flagged some safety signals worth continued monitoring (Source: Diabetes, Obesity & Metabolism, 2026).

Is Mazdutide Available Outside China?

Not right now. Mazdutide is currently in the trial and regulatory process in China, developed by a Chinese biotech company. It hasn't gone through FDA review, and it isn't approved or sold in the US.

That said, trials like GLORY-2 are exactly the kind of data that eventually shapes global drug approval decisions. If the dual-agonist approach keeps performing well in larger trials, it becomes a template other companies (and potentially the same one, seeking Western approval) will follow. If you want to keep tabs on what other next-generation combos are moving through the pipeline, our guide to new weight loss peptides tracks the ones furthest along.

What This Means If You're Currently Considering a GLP-1 Drug

If you're picking between what's actually available to you right now -- semaglutide or tirzepatide -- mazdutide doesn't change your decision today. It's not an option you can access.

But it does tell you something useful: the drugs coming after tirzepatide are going to keep adding receptor targets, not simplifying. If your goal is understanding where this category is headed, understanding dual and triple agonist mechanics now will make future headlines easier to decode. Our dual vs. triple agonist breakdown is a good next stop for that.

FAQ

What is mazdutide? Mazdutide is a peptide being studied in China that activates both GLP-1 and glucagon receptors. It's designed for weight loss and metabolic health, similar in category to semaglutide and tirzepatide but with a different mechanism.

What did the GLORY-2 trial find? GLORY-2 tested 9mg mazdutide for weight reduction in Chinese adults with obesity, building on earlier trial data that reported meaningful weight loss at that dose over roughly a year of treatment (Source: PubMed).

Is mazdutide better than semaglutide or tirzepatide? It's too early to say definitively. Early data suggests mazdutide's weight loss results are in a similar range to tirzepatide's, but there hasn't been a large head-to-head trial directly comparing them yet.

Can I get mazdutide in the US? No. It's not FDA-approved and isn't currently available outside trials in China.

Why does the glucagon receptor matter? Glucagon receptor activation is linked to increased energy expenditure, meaning the body may burn more calories at rest -- a mechanism separate from appetite suppression that GLP-1-only drugs rely on.

The Takeaway

GLORY-2 isn't a drug you can buy or ask your doctor about yet, but it's a preview of where obesity treatment is heading. Multi-receptor peptides like mazdutide are becoming the norm, not the exception, and understanding how they work now will help you make sense of whatever gets FDA attention next.

If you want to go deeper into how these mechanisms stack up against what's already approved, start with our semaglutide vs. tirzepatide guide and work forward from there.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The author shares personal experience and published research -- not medical recommendations.

Sources

1. GLORY-2 Randomized Clinical Trial reference, PubMed, 2026
2. Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis, BMJ, 2026
3. GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study, Diabetes, Obesity & Metabolism, 2026
4. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes, The Lancet, 2026
5. Tirzepatide, cardiovascular outcomes and mortality in obesity and diabetes: a systematic review and meta-analysis, Diabetes Research and Clinical Practice, 2026